QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=736A209A1506BE54CA504460A49BD548;jsessionid=F037F42736D2F2F4ADBBA108DA161310;jsessionid=61BFD254DD974CA7B6D72E8654F377EB;jsessionid=5D9E0658EC8E967FBBE483B187B302DF;jsessionid=FA4F9F5210C7AD4EBA5D07E8ECB16DA8 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. Abnormal open states patterns in the ATXN2 DNA sequence depends on the CAG repeats length.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=736A209A1506BE54CA504460A49BD548;jsessionid=F037F42736D2F2F4ADBBA108DA161310;jsessionid=61BFD254DD974CA7B6D72E8654F377EB;jsessionid=5D9E0658EC8E967FBBE483B187B302DF;jsessionid=FA4F9F5210C7AD4EBA5D07E8ECB16DA8